Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

QYuns Out-Licenses Ex-China Rights for Autoimmune Portfolio to Seneca

publication date: Nov 1, 2019

Jiangsu QYuns Therapeutics agreed to out-license ex-China rights to its portfolio of six autoimmune disease mAb candidates to Seneca Biopharma of Maryland. The agreement does not include any upfront, milestone or royalty payments, though presumably QYuns will manufacture the drugs for Seneca to commercialize. QYuns developed the products, which are mostly interleukin antibodies. using its novel rabbit-based discovery platform. After final agreement, Seneca's lead drug will be QYuns' QX005N, an IL-4Rα mAb aimed at asthma and atopic dermatitis that has a potential market in the US of $1 billion. More details....

Stock Symbol: (NSDQ: SCNA)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.